Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Janux Therapeutics (JANX) Shares Outstanding (Weighted Average): 2021-2025

Historic Shares Outstanding (Weighted Average) for Janux Therapeutics (JANX) over the last 5 years, with Sep 2025 value amounting to $60.1 million.

  • Janux Therapeutics' Shares Outstanding (Weighted Average) rose 15.20% to $60.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $60.1 million, marking a year-over-year increase of 15.20%. This contributed to the annual value of $52.5 million for FY2024, which is 13.68% up from last year.
  • According to the latest figures from Q3 2025, Janux Therapeutics' Shares Outstanding (Weighted Average) is $60.1 million, which was up 1.55% from $59.2 million recorded in Q2 2025.
  • Janux Therapeutics' 5-year Shares Outstanding (Weighted Average) high stood at $60.1 million for Q3 2025, and its period low was $38.0 million during Q1 2021.
  • In the last 3 years, Janux Therapeutics' Shares Outstanding (Weighted Average) had a median value of $51.9 million in 2024 and averaged $51.1 million.
  • Data for Janux Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY increased of 23.95% (in 2024) over the last 5 years.
  • Janux Therapeutics' Shares Outstanding (Weighted Average) (Quarterly) stood at $41.6 million in 2021, then grew by 0.12% to $41.7 million in 2022, then climbed by 10.81% to $46.2 million in 2023, then climbed by 13.68% to $52.5 million in 2024, then rose by 15.20% to $60.1 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $60.1 million in Q3 2025, compared to $59.2 million in Q2 2025 and $59.1 million in Q1 2025.